Cardiovascular effects of estrogen

American Journal of Hypertension

Volumn 14, Issue 6 II, 2001, Pages

  Tolbert, Todd ^a   Oparil, Suzanne ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Cardiovascular disease; Estrogen; Vascular injury

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; OSTEOPONTIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; CONFERENCE PAPER; DRUG MECHANISM; FIBROBLAST; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; INTIMA; PRIORITY JOURNAL; VASCULAR SMOOTH MUSCLE;

EID: 0034986201     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0895-7061(01)02087-8     Document Type: Conference Paper

References (70)

1. Cardiovascular disease in women: Statement for healthcare professionals from the American Heart Association
2. The clinical aspects of estrogen and the cardiovascular system
3. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence
4. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women
5. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease
6. Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy
7. Postmenopausal hormone therapy and risk of cardiovascular disease and hip fracture in a cohort of Swedish women
8. Hormone replacement and incidence of acute myocardial infarction. A population-based nested case-control study
9. Decreased mortality in users of estrogen replacement therapy
10. Postmenopausal estrogen use and heart disease risk factors in the 1980s
11. Prior to use of estrogen replacement therapy, are users healthier than non-users?
12. Estrogens for prevention of coronary heart disease: Putting the brakes on the bandwagon
13. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
14. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled study
15. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
16. Hormone replacement therapy and heart disease prevention-experimentation trumps observation
17. Postmenopausal hormone therapy and stroke: The Heart and Estrogen-progestin Replacement Study (HERS)
18. Design of the Women's Health Initiative clinical trial and observational study
19. Effects of estrogen replacement on the progression of coronary artery atherosclerosis
20. Effects of estrogen replacement therapy on serum lipid values and angiographically defined coronary artery disease in postmenopausal women
21. The Million Women Study: Design and characteristics of the study population
22. Megatrials of hormonal replacement therapy
23. The effects of hormone replacement therapy on echocardiographic basic cardiac functions in postmenopausal women
24. Effect of hormone replacement therapy on left ventricular hypertrophy
25. Effects of transdermal 17β-estradiol on left ventricular anatomy and performance in hypertensive women
26. Enhancement of post-ischemic myocardial function by chronic 17 β-estradiol treatment: Role of alterations in glucose metabolism
27. Vascular smooth muscle cells possess estrogen receptors and respond to estrogen
28. Non-genomic effects of estrogen and the vessel wall
29. Cardiac myocytes and fibroblasts contain functional estrogen receptors
30. Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries in premenopausal women
31. Premarin-induced increases in coronary and uterine blood flow in nonpregnant sheep
32. Quantitative assessment with intracoronary ultrasound of the mechanisms of restenosis after percutaneous transluminal coronary angioplasty and directional coronary atherectomy
33. Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions
34. Estrogen replacement therapy after coronary angioplasty in women
35. Estrogen replacement therapy and outcome of coronary balloon angioplasty in postmenopausal women
36. Conjugated equine estrogens inhibit progression of atherosclerosis but have no effect on intimal hyperplasia or arterial remodeling induced by balloon catheter injury in monkeys
37. Inhibition of coronary artery atherosclerosis: Lack of effect of added progesterone
38. A morphologic and permeability study of luminal smooth muscle cells after arterial injury in the rat
39. Estrogen reduces myointimal proliferation after balloon injury of rat carotid artery
40. Medroxyprogesterone attenuates estrogen-mediated inhibition of neointima formation after balloon injury of the rat carotid artery
41. Sexually dimorphic response of the balloon-injured rat carotid artery to hormone treatment
42. Estrogen-induced vasoprotection is estrogen receptor dependent: Evidence from the balloon injured rat carotid artery model
43. Mithramycin inhibits myointimal proliferation after balloon injury of the rat carotid artery in vivo
44. Estrogen inhibits vascular smooth muscle cell-dependent adventitial fibroblast migration in vitro
45. Direct in vivo evidence demonstrating neointimal migration of adventitial fibroblasts after balloon injury of rat carotid arteries
46. Estrogen attenuates the adventitial contribution to neointimal formation in injured rat carotid arteries
47. Effects of short-term estrogen treatment on the neointimal response to balloon injury of rat carotid artery
48. Estrogen attenuates integrin β3-dependent adventitial fibroblast migration after inhibition of osteopontin production in vascular smooth muscle cells
49. Clinically used estrogens differentially inhibit human aortic smooth muscle cell growth and mitogen-activated protein kinase activity
50. Comparison of the effects of conjugated estrogen treatment on blood lipid and lipoprotein levels when initiated in the first or fifth postmenopausal year
51. Estrogen and progestin, lipoprotein (a), and the risk of recurrent coronary heart disease events after menopause
52. Combined oestrogen-progestogen replacement does not inhibit low-density lipoprotein oxidation in postmenopausal women
53. Antioxidant protection of LDL by physiological concentrations of 17β-estradiol
54. Hormone replacement therapy enhances postprandial lipid metabolism in postmenopausal women
55. Plasma cholesteryl ester fatty acid composition, insulin sensitivity, the menopause and hormone replacement therapy
56. Regulation of platelet aggregation and adenosine triphosphate release in vitro by 17β-estradiol and medroxyprogesterone acetate in postmenopausal women
57. Lipoprotein(a) levels and isoforms and fibrinolytic activity in postmenopause-influence of hormone replacement therapy
58. Fibrinolytic potential is significantly increased by oestrogen treatment in postmenopausal women with mild dyslipidaemia
59. Effects of hormone replacement therapy on hemostatic cardiovascular risk factors
60. Hormone replacement therapy, inflammation, and hemostasis in elderly women
61. Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis
62. Hormone replacement therapy and circulating ICAM-1 in postmenopausal women - A randomized controlled trial
63. Hormone replacement therapy and plasma homocysteine levels
64. Serum level of vascular endothelial growth factor is decreased by hormone replacement therapy in postmenopausal women without hypercholesterolemia
65. Progestins abrogate estrogen-induced changes in the insulin-like growth factor axis
66. Increased plasma concentrations of TGF-β1 after hormone replacement therapy
67. C-reactive protein in patients with chronic stable angina: Differences in baseline serum concentration between women and men
68. Hormone replacement therapy and increased plasma concentration of C-reactive protein
69. Effect of postmenopausal hormones on inflammation-sensitive proteins: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study